Showing results (21-30 of 196) with videos related to
Sort By:
Pageof 20
Contemporary Clinical Trials|August 22, 2020
Comparison of Phase I-II designs with parametric or semi-parametric models using two different risk-benefit trade-off criteriaAndrew G Chapple, Peter F ThallClinical Trials (London, England)|March 4, 2009
Bayesian model averaging in meta-analysis: vitamin E supplementation and mortalityDonald Berry, J Kyle Wathen, Margaret NewellBiometrics|September 2, 2004
Dose-finding based on efficacy-toxicity trade-offsPeter F Thall, John D CookPharmaceutical Statistics|August 17, 2018
Subgroup-specific dose finding in phase I clinical trials based on time to toxicity allowing adaptive subgroup combinationAndrew G Chapple, Peter F ThallJournal of Biopharmaceutical Statistics|June 2, 2012
Adaptive randomization to improve utility-based dose-finding with bivariate ordinal outcomesPeter F Thall, Hoang Q NguyenClinical Advances in Hematology & Oncology : H&O|March 25, 2006
Some ethical issues in phase II trials in acute leukemiaPeter F Thall, Elihu H EsteyBiometrics|October 28, 2018
A hybrid phase I-II/III clinical trial design allowing dose re-optimization in phase IIIAndrew G Chapple, Peter F ThallBiometrics|July 6, 2019
An adaptive trial design to optimize dose-schedule regimes with delayed outcomesRuitao Lin, Peter F Thall, Ying YuanJournal of the Royal Statistical Society. Series C, Applied Statistics|May 21, 2019
Optimizing natural killer cell doses for heterogeneous cancer patients on the basis of multiple event timesJuhee Lee, Peter F Thall, Katy RezvaniPageof 20